MU-OPIOID RECEPTOR ANTAGONISTS AND THEIR ROLE IN TREATMENT OF CHRONIC CONSTIPATION
Constipation disproportionately affects older adults, with a prevalence of 50% in community-dwelling elderly and 74% in nursing-home residents. Loss of mobility, medications, underlying diseases, impaired anorectic sensation, and ignoring calls to defecate are as important as dyssynergic defecation or irritable bowel syndrome in causing constipation. Opioid antagonists not only have well-established indications in the reversal of life-threatening opioid toxicity but also hold considerable promise for other applications in palliative care practice, particularly management of opioid-induced constipation (OIC). This review summarizes the pharmacology of new peripherally acting mu (Âµ) opioid receptor antagonists (PAMORA).
2. Papadakis MA, McPhee SJ. Current medical diagnosis and treatment. 54th Ed. USA: McGraw Hill; 2015.
3. Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol 2011;25:16B-21B.
4. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9.
5. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-93.
6. Sonnenberg A, Chang J. Time trends of physician visits for Crohnâ€™s disease and ulcerative colitis in the United States. Inflammatory Bowel Dis 2006;14:249â€“52.
7. Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Ther Adv Gastroenterol 2012;5:233â€“47.
8. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am 2007;36:687â€“711.
9. Tripathi KD. Essentials of medical pharmacology. 7th ed. New Delhi: JayPee Brothers; 2013.
10. Giorgio RD, Ruggeri E, Stanghellini V, Eusebi LH, Bazzoli F, Chiarioni G. Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterol 2015;15:130.
11. Bansal N, Sachdeva M, Jain P, Ranjan P, Arora A. Pharmacological update for chronic constipation. Int Med Sci Acad 2012;25:23-5.
12. Manara L, Bianchi G, Ferretti P, Tavani A. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid investigational sites. J Pharmacol Exp Ther 1986;237:945â€“9.
13. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009;155:11â€“7.
14. Chung HH. The novel role of opioid-receptors in gastroenterology. J Gastroenterol Hepatol Res 2013;2:614â€“7.
15. Aurilio C, Pace MC, Pota V, Sansone P. Opioid induced constipation. InTech; 2012. p. 81â€“8.
16. Clemens KE, Klaschik E. Managing opioid-induced constipation in advanced illness: Focus on methylnaltrexone bromide. Ther Clin Risk Manag 2010;6:77â€“82.
17. Brown D, Goldberg L. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181â€“91.
18. Russell J, Bass P, Goldberg L, Schuster C, Merz H. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982;78:255â€“61.
19. Amin H, Sopchak A, Foss J, Esposito B, Roizen M, Camporesi E. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilator response. Anesth Analg 1994;78:701â€“5.
20. Cassel JA, Daubert JD, DeHaven RN. Alvimopan binding to the micro-opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol 2005;520:29â€“36.
21. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41:984â€“93.
22. Kotake AN, Kuwahara SK, Burton E, McCoy CE, Goldberg LI. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans. Xenobiotica 1989;19:1247â€“54.
23. Jeffrey S. FDA okays methylnaltrexone (Relistor) for opioid constipation. Medscape; 2014. Available from URL: http://www.medscape.com/viewarticle/832609#vp_2. [Last accessed 20 Jul 2017]
24. FDA Approves Relistor for Opioid-Induced Constipation; 2009. Available from URL: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2014/021964s010lbl.pdf. [Last accessed on 20 Jul 2017]
25. Thomas J, Karver S, Austin GC, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:22.
26. Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 1994;37:2262â€“5.
27. Alvimopan Product Label as approved by the FDA on May 20; 2008. Available from: URL: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2008/021775lbl.pdf.
28. Linn AJ, Steinbrook RA. Peripherally restricted Âµ-opioid receptor antagonists: a review. Tech Reg Anesth Pain Manag 2007;11:27â€’32.
29. Foss J, Marbury TC, Melikian A, Schmith V, Du W, Wallin B. Pharmacokinetics of alvimopan, a novel, oral, peripherally acting mu-opioid receptor (PAM-OR) antagonist, and its primary metabolite in the elderly. Pharmacotherapy 2005;25:1505
30. Drugbank. Alvimopan; 2008. Available from: URL: https://www.drugbank.ca/drugs/DB06274/. [Last accessed on 20 Jul 2017]
31. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137:428â€“40.
32. Reinhold J. New drugs; 2008. Available from: URL: http://www.cecity.com/ncpa/2009_projects/new_drugs_2008/article.htm. [Last accessed on 20 Jul 2017]
33. Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol 2014;7:345â€“58.
34. FDA approves MOVANTIKâ„¢ (naloxegol) Tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; 2014. Available from: URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204760s002s003lbl.pdf. [Last accessed on 20 Jul 2017].
35. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Delivery Rev 2002;54:459â€“76.
36. Faassen F, Vogel G, Spanings H, Vromans H. Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm 2003;263:113â€“22.
37. Anderson P. FDA okays naloxegol (Movantik) in opioid-induced constipation; 2014. Available from: URL: http://www. medscape.com/viewarticle/831780. [Last accessed on 20 Jul 2017]
38. Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of Naloxegol. J Clin Pharmacol 2014;54:1375â€“82.
39. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioidâ€‘induced constipation in patients with nonâ€‘cancer pain. N Engl J Med 2014;370:2387â€‘96.
40. Anantharamu T, Sharma S, Gupta AK, Dahiya N, Brashier DBS, Sharma AK. Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother 2015;6:188â€“92.
41. FDA Approves symproic (naldemedine) for the treatment of opioid-induced constipation; 2017. Available from: URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf. [Last accessed 20 Jul 2017]
42. Drugbank. Naldemedine; 2016. Available from: URL: https://www.drugbank.ca/drugs/DB11691. [Last accessed on 20 Jul 2017].
43. Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2017;1:1â€“11.
44. Migoya E, Fukumura K, Yamada T, Ferreira JA. Effect of naldemedine, a peripherally acting mu-opioid receptor antagonist on QT interval. J Pain 2016;17:S81.